Vitrolife AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 75.19.
Vitrolife AB's Days Inventory for the
three
months ended in Mar. 2026 was 118.43.
Vitrolife AB's Days Payable for the
three
months ended in Mar. 2026 was 53.65.
Therefore, Vitrolife AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 139.97.
Vitrolife AB (OSTO:VITR) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Vitrolife AB Cash Conversion Cycle Related Terms
Vitrolife AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VITR vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Vitrolife AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Vitrolife AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (OSTO:VITR) has a Cash Conversion Cycle of 139.97 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Cash Conversion Cycle too high?
Vitrolife AB's current Cash Conversion Cycle is 139.97. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Vitrolife AB's value of 139.97 is 10.8% below this industry median. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Cash Conversion Cycle compare to ABT and SYK?
Vitrolife AB's Cash Conversion Cycle of 139.97 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Vitrolife AB's value of 139.97 is 10.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Cash Conversion Cycle of 139.97 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Cash Conversion Cycle is 139.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.30, compared to a current price of kr89.50 — trading 44.9% below its estimated fair value. The current Cash Conversion Cycle is 139.97 and 10.8% below the Medical Devices & Instruments industry median of 156.96. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Cash Conversion Cycle is 139.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr89.50 is trading 44.9% below its estimated GF Value™ of kr162.30.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
Cash Conversion Cycle: 139.97
GF Value™: kr162.30 vs. price of kr89.50 (44.9% below fair value)
Industry Position: 10.8% below the Medical Devices & Instruments median
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
